<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 11:02:39 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>Positive Phase 2 Data for LGMD2i | BridgeBio</title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <meta
      name="description"
      content="BridgeBio and its affiliate company ML Bio Solutions announced positive data from the Phase 2 study of BBP-418 in patients with LGMD2i. Learn more today!"
    />
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta
      property="og:title"
      content="Positive Phase 2 Data for LGMD2i | BridgeBio"
    />
    <meta
      property="og:description"
      content="BridgeBio and its affiliate company ML Bio Solutions announced positive data from the Phase 2 study of BBP-418 in patients with LGMD2i. Learn more today!"
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2022-03-14T11:30:00+00:00"
    />
    <meta
      property="article:modified_time"
      content="2022-06-22T20:28:29+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2019/02/BridgeBio_Share.png"
    />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="600" />
    <meta property="og:image:type" content="image/png" />
    <meta name="author" content="Kaitlyn Reilly" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Kaitlyn Reilly" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="9 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/",
            "url": "https://bridgebio.com/news/bridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/",
            "name": "Positive Phase 2 Data for LGMD2i | BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "datePublished": "2022-03-14T11:30:00+00:00",
            "dateModified": "2022-06-22T20:28:29+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/cd17f1fef87fbb503cdc4095ec5b3c60"
            },
            "description": "BridgeBio and its affiliate company ML Bio Solutions announced positive data from the Phase 2 study of BBP-418 in patients with LGMD2i. Learn more today!",
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/"
                ]
              }
            ]
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)"
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/cd17f1fef87fbb503cdc4095ec5b3c60",
            "name": "Kaitlyn Reilly",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/589c3adcd55b12c15da3e878a123f424?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/589c3adcd55b12c15da3e878a123f424?s=96&d=mm&r=g",
              "caption": "Kaitlyn Reilly"
            },
            "sameAs": ["http://Dev%20Team"],
            "url": "https://bridgebio.com/author/kaitlynreilly/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/styleb503.css?ver=1734517800"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-cssb503.css?ver=1734517800"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrustb503.css?ver=1734517800"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scriptsb503.js?ver=1734517800"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modalb503.js?ver=1734517800"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/5373.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../index984a.html?p=5373" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embed5766.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embedd680?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-announces-positive-phase-2-data-for-limb-girdle-muscular-dystrophy-type-2i-lgmd2i%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-5373 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle
              Muscular Dystrophy Type 2i (LGMD2i)
            </h1>
            <section>
              <p>
                <em
                  >&#8211; 43% increase in the ratio of glycosylated
                  alpha-dystroglycan (αDG) to total αDG from baseline were
                  measured across all three dosing cohorts, signifying the oral
                  therapy has the potential to address both the root cause of
                  LGMD2i and drive functional improvements for patients</em
                >
              </p>

              <p>
                <em
                  >&#8211; Average of 70% reduction in creatine kinase (CK), a
                  key marker of muscle breakdown, after 90 days of treatment and
                  average 77% reduction after 180 days</em
                >
              </p>

              <p>
                <em
                  >&#8211; Increase in velocity in the 10-meter walk test
                  (10MWT) at day 90 and 180, which is an improvement over the
                  decline in velocity seen in the natural history data</em
                >
              </p>

              <p>
                <em
                  >&#8211; If the development program is successful, BridgeBio
                  believes BBP-418 could be the first approved therapy for the
                  treatment of patients with LGMD2i</em
                >
              </p>

              <p>
                <em
                  >&#8211; BridgeBio to host investor call on March 14, 2022 at
                  8:00 AM ET</em
                >
              </p>

              <p>
                <strong>PALO ALTO, CA – March 14, 2022 — </strong>BridgeBio
                Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a
                commercial-stage biopharmaceutical company focused on genetic
                diseases and cancers, and its affiliate company ML Bio
                Solutions, today announced positive data from the Phase 2 study
                of BBP-418 in patients with limb-girdle muscular dystrophy type
                2i (LGMD2i). The results are featured in a poster at the
                Muscular Dystrophy Association (MDA) 2022 Annual Meeting, taking
                place in Nashville, Tennessee on March 13 – 16, 2022.
              </p>

              <p>
                BridgeBio believes these initial results indicate the potential
                for BBP-418 to increase glycosylation of αDG and drive
                functional improvements for patients, as well as reduce CK, a
                key marker of muscle breakdown. Furthermore, the 90- and 180-day
                data show improvements on walk tests from baseline, which the
                Company believes suggests a potential impact on clinical
                function and on the rate of disease progression.
              </p>

              <p>
                “To date, people with LGMD2i have no approved disease-modifying
                treatment options. Many of these patients see their quality of
                life deteriorate rapidly and lose their functional independence,
                including their ability to walk. Our preliminary trial data
                holds promise for this unmet patient need as our investigational
                therapy is shown to be generally well-tolerated and to improve
                several key markers associated with a patient’s decline,” said
                Douglas Sproule, M.D., M.Sc., chief medical officer of ML Bio
                Solutions. ML Bio Solutions, based in Charlotte, North Carolina,
                is the affiliate company of BridgeBio that is focused on
                developing BBP-418 for LGMD2i.
              </p>

              <p>
                BridgeBio plans to engage with regulatory health bodies in 2022
                to discuss potential paths to approval and intends to initiate a
                Phase 3 clinical trial in the second half of the year. At MDA
                2022, BridgeBio is also presenting Phase 1 trial data of BBP-418
                in healthy volunteers to support its LGMD2i program. The Phase 1
                study demonstrated broad tolerability across a wide range of
                dosing, including doses beyond expected therapeutic range. No
                dose limiting toxicity was observed. 
              </p>

              <p>
                The Phase 2 trial enrolled 14 participants, including both
                ambulatory and non-ambulatory patients with LGMD2i. The
                open-label study is designed to explore the safety and
                tolerability, feasibility, and usefulness of selected clinical
                efficacy and pharmacodynamic (PD) assessment of patients with
                LGMD2i receiving ascending doses of BBP-418 across three
                cohorts. Based on the data observed after 90 and 180 days of
                treatment, BridgeBio observed:
              </p>

              <ul class="wp-block-list">
                <li>
                  Participants showed an average 0.21 or 43% increase in the
                  ratio of glycosylated αDG to total αDG, signifying that the
                  oral therapy has the potential to address both the root cause
                  of LGMD2i and drive functional improvements for patients
                </li>
                <li>
                  Participants showed statistically significant declines in all
                  cohorts for CK, of 70% at day 90 for all cohorts and 77% at
                  day 180 for cohorts 1 and 2. 11 of 12 participants received at
                  least 50% reduction in CK with 75% of participants reaching 2x
                  the normal range, suggesting a reduction in muscle breakdown
                </li>
                <li>
                  All cohorts demonstrated a 0.08 m/sec (3%) increase in 10MWT
                  velocity at day 90 and 0.12 m/sec (4%) increase at day 180 for
                  cohorts 1 and 2. This result is encouraging in correlating the
                  positive biomarker changes to potential clinical outcomes
                </li>
                <li>
                  The 10MWTs were measured at six months and compare favorably
                  to natural history data where the same patients demonstrated a
                  decline of 0.12 m/sec in the 10MWT in the 6-months prior to
                  enrollment in the Phase 2 study
                </li>
                <li>
                  BBP-418 was well-tolerated across a wide range of dose levels
                  with no treatment-related serious adverse events, dose
                  limiting toxicities or discontinuations observed
                </li>
              </ul>

              <p>
                “The positive results from the Phase 2 study exceed expectations
                and are incredibly exciting as they demonstrate consistent
                improvements in key markers of muscle function and support
                further study,” said Amy Harper, M.D., professor in the
                department of neurology at Virginia Commonwealth University
                (VCU) and primary investigator of the Phase 2 clinical trial in
                LGMD2i. “The close collaboration with BridgeBio and ML Bio
                Solutions on this trial has provided patient focused data that
                addresses a serious unmet need in a rare disease.”
              </p>

              <p>
                With approximately 7,000 patients in the U.S. and European Union
                with potentially treatable mutations, LGMD2i is an inherited
                autosomal recessive muscular dystrophy caused by the mutation of
                fukutin-related protein (FKRP), which results in
                hypoglycosylation of αDG. BBP-418 is designed to allow the
                muscle cell to properly glycosylate αDG, allowing αDG to
                function normally and potentially resulting in improved muscle
                strength and function for patients. If the development program
                is successful, the Company believes BBP-418 could be the first
                approved therapy for the treatment of patients with LGMD2i.
              </p>

              <p>
                Focused execution is BridgeBio’s top priority as it advances its
                pipeline of high-quality programs to help patients as quickly as
                possible. The Company remains dedicated to strategically
                developing and delivering transformative medicines for genetic
                diseases and cancers with unmet need.
              </p>

              <p><strong>Webcast Information</strong></p>

              <p>
                BridgeBio will host an investor call and simultaneous webcast to
                share updates on the Phase 2 data for limb-girdle muscular
                dystrophy type 2i on March 14, 2022 at 8:00 AM ET. To access
                this call, dial 800-379-2666 and enter conference ID 3562087. A
                link to the webcast may be accessed from the event calendar page
                of BridgeBio’s website at <a
                  href="https://investor.bridgebiodev.wpengine.com/news-and-events/event-calendar"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong
                    >https://investor.bridgebiodev.wpengine.com/</strong
                  ></a
                >. A replay of the conference call and webcast will be archived
                on the Company’s website and will be available for at least 30
                days following the event. 
              </p>

              <p>
                <strong
                  >About Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)</strong
                >
              </p>

              <p>
                LGMD2i is a monogenic autosomal recessive disease caused by
                partial loss of function mutations in the FKRP gene, and these
                FKRP mutations impair glycosylation of αDG, a protein associated
                with stabilizing muscle cells. LGMD2i is a disease that has
                pediatric symptomatic onset with most individuals developing
                manifestations of disease between 5 and 18 years of
                age. Clinical manifestations typically present as a skeletal
                myopathy affecting the lower and then upper limbs, which is
                commonly later accompanied by respiratory muscle and cardiac
                muscle involvement. Patients who harbor a homozygous genotype
                typically develop disease manifestations during late childhood
                with progression to loss of independent ambulation (25%),
                assisted ventilation (5%), and cardiomyopathy (10%) in
                adulthood. Cardiomyopathy is progressive, with an annual loss of
                0.4% of left ventricular ejection fraction (LVEF). Patients with
                heterozygous genotypes have an earlier childhood onset with a
                more severe clinical course, rapid loss of mobility by 20 years
                of age, more frequent cardiac involvement (25%), and eventual
                respiratory failure by 30 years of age in nearly all cases.
              </p>

              <p><strong>About BridgeBio Pharma, Inc.</strong></p>

              <p>
                BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage
                biopharmaceutical company founded to discover, create, test and
                deliver transformative medicines to treat patients who suffer
                from genetic diseases and cancers with clear genetic drivers.
                BridgeBio’s pipeline of over 30 development programs ranges from
                early science to advanced clinical trials, and its commercial
                organization is focused on delivering the company’s first two
                approved therapies. BridgeBio was founded in 2015 and its team
                of experienced drug discoverers, developers, and innovators are
                committed to applying advances in genetic medicine to help
                patients as quickly as possible. For more information visit <a
                  href="../../index.html"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>bridgebiodev.wpengine.com</strong></a
                > and follow us on <a
                  href="https://www.linkedin.com/company/bridgebio"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>LinkedIn</strong></a
                > and <a
                  href="https://twitter.com/BridgeBioPharma"
                  target="_blank"
                  rel="noreferrer noopener"
                  ><strong>Twitter</strong></a
                >.
              </p>

              <p>
                <strong
                  >BridgeBio Pharma, Inc. Forward-Looking Statements</strong
                >
              </p>

              <p>
                This press release contains forward-looking statements.
                Statements we make in this press release may include statements
                that are not historical facts and are considered forward-looking
                within the meaning of Section 27A of the Securities Act of 1933,
                as amended (the “Securities Act”), and Section 21E of the
                Securities Exchange Act of 1934, as amended (the “Exchange
                Act”), which are usually identified by the use of words such as
                “anticipates,” “believes,” “estimates,” “expects,” “intends,”
                “may,” “plans,” “projects,” “seeks,” “should,” “will,” and
                variations of such words or similar expressions.  We intend
                these forward-looking statements to be covered by the safe
                harbor provisions for forward-looking statements contained in
                Section 27A of the Securities Act and Section 21E of the
                Exchange Act and are making this statement for purposes of
                complying with those safe harbor provisions.  These
                forward-looking statements, including statements relating to the
                timing and success of ML Bio Solutions’ clinical trials of
                BBP-418 for the treatment of LGMD2i, expectations, plans and
                prospects regarding ML Bio Solutions’ regulatory approval
                process for BBP-418, the ability of BBP-418 to treat LGMD2i in
                humans, the potential for BBP-418 to be the first approved
                therapy for the treatment of LGMD2i and the timing and success
                of BridgeBio’s clinical trials and development pipeline, reflect
                our current views about our plans, intentions, expectations,
                strategies and prospects, which are based on the information
                currently available to us and on assumptions we have made.
                Although we believe that our plans, intentions, expectations,
                strategies and prospects as reflected in or suggested by those
                forward-looking statements are reasonable, we can give no
                assurance that the plans, intentions, expectations or strategies
                will be attained or achieved.  Furthermore, actual results may
                differ materially from those described in the forward-looking
                statements and will be affected by a number of risks,
                uncertainties and assumptions, including, but not limited to, ML
                Bio Solutions’ ability to continue and complete its clinical
                trials of BBP-418 for the treatment of LGMD2i, past data from
                preclinical studies not being indicative of future data from
                clinical trials, ML Bio Solutions’ ability to advance BBP-418 in
                clinical development according to its plans, the ability of
                BBP-418 to be the first approved therapy for the treatment of
                patients with LGMD2i, BridgeBio’s ability to advance its
                clinical trials and development pipeline, the success of
                BridgeBio’s approved drugs, as well as those risks set forth in
                the Risk Factors section of BridgeBio Pharma’s Annual Report on
                Form 10-K for the year ended December 31, 2021, and BridgeBio
                Pharma’s other SEC filings. Moreover, BridgeBio operates in a
                very competitive and rapidly changing environment in which new
                risks emerge from time to time. Except as required by applicable
                law, we assume no obligation to update publicly any
                forward-looking statements, whether as a result of new
                information, future events or otherwise.
              </p>

              <p>
                <strong>BridgeBio Media Contact:</strong><br />Grace Rauh<br /><a
                  href="../../cdn-cgi/l/email-protection.html#92f5e0f3f1f7bce0f3e7fad2f0e0fbf6f5f7f0fbfdf6f7e4bce5e2f7fcf5fbfcf7bcf1fdff"
                  ><strong
                    ><span
                      class="__cf_email__"
                      data-cfemail="99feebf8fafcb7ebf8ecf1d9fbebf0fdfefcfbf0f6fdfcefb7eee9fcf7fef0f7fcb7faf6f4"
                      >[email&#160;protected]</span
                    ></strong
                  ></a
                ><br />(917) 232-5478
              </p>

              <p>
                <strong>BridgeBio Investor Contact:</strong><br />Katherine
                Yau<br /><a
                  href="../../cdn-cgi/l/email-protection.html#a6cdc7d2cec3d4cfc8c388dfc7d3e6c4d4cfc2c1c3c4cfc9c2c3d088d1d6c3c8c1cfc8c388c5c9cb"
                  ><strong
                    ><span
                      class="__cf_email__"
                      data-cfemail="a4cfc5d0ccc1d6cdcac18addc5d1e4c6d6cdc0c3c1c6cdcbc0c1d28ad3d4c1cac3cdcac18ac7cbc9"
                      >[email&#160;protected]</span
                    ></strong
                  ></a
                ><br />(516) 554-5989
              </p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4><a href="../index.html" class="red uppercase">News</a></h4>
            <small class="date">03.14.2022</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#036a6d656c4361716a676466616a6c2d606c6e"
              ><span
                class="__cf_email__"
                data-cfemail="cca5a2aaa38caebea5a8aba9aea5a3e2afa3a1"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
